Mineralys Therapeutics, Inc. Common Stock
MLYS
$23.69
-5.43%
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for diseases driven by dysregulated aldosterone, primarily hypertension and related cardiorenal conditions. Its lead candidate, lorundrostat, is a proprietary, orally administered aldosterone synthase inhibitor designed to directly reduce aldosterone production, positioning the company as a potential disruptor in a large, established cardiovascular market dominated by older drug classes. The current investor narrative is driven by the clinical development progress of lorundrostat, with the stock's volatility reflecting binary sentiment swings based on trial data readouts, regulatory milestones, and competitive developments in the hypertension and chronic kidney disease treatment landscape.…
MLYS
Mineralys Therapeutics, Inc. Common Stock
$23.69
MLYS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Mineralys Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $30.80 and implied upside of +30.0% versus the current price.
Average Target
$30.80
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$19 - $31
Analyst target range
The stock is covered by at least six analysts, as evidenced by the revenue and EPS estimate data, and institutional ratings show a consistently bullish bias with recent actions from firms like BofA Securities, Stifel, HC Wainwright, and Wells Fargo all maintaining Buy or Overweight ratings. The consensus sentiment is strongly positive, though the absence of a specific average price target in the provided data requires inference; the wide range of estimated future EPS (from $2.21 to $11.00) and revenue underscores the high uncertainty around lorundrostat's commercial potential. The target price range implied by these estimates is exceptionally broad, with the high-end scenario pricing in robust commercial success and market penetration, while the low-end likely reflects clinical or regulatory setbacks; the recent cluster of reaffirmed Buy ratings in late 2025 and early 2026 suggests analysts remain supportive despite the stock's price decline, viewing it as a temporary setback rather than a fundamental deterioration.
Bulls vs Bears: MLYS Investment Factors
The bull and bear cases for MLYS are starkly opposed, representing a classic high-risk, high-reward biotech investment. The bull case is anchored by a fortress balance sheet, unwavering analyst support, and a deeply oversold technical setup that could amplify gains on positive news. The bear case highlights the existential risks of a pre-revenue company with a single clinical asset, persistent cash burn, and severe negative momentum. Currently, the bear side has stronger near-term evidence, given the stock's 35% six-month decline, high short interest, and lack of imminent catalysts to reverse sentiment. The single most important tension in the investment debate is the binary outcome of lorundrostat's clinical development: success unlocks multi-billion dollar revenue potential, while failure could render the equity nearly worthless, with the stock potentially retesting its 52-week low of $12.59.
Bullish
- Strong Balance Sheet with Zero Debt: The company has a robust current ratio of 43.76 and carries zero debt, providing significant financial flexibility to fund its clinical development without the pressure of debt service. This strong liquidity position, bolstered by a recent $96.7 million equity raise in Q4 2025, reduces near-term financing risk and supports continued R&D investment in lorundrostat.
- Analyst Consensus Remains Bullish: Despite the stock's 34.94% decline over six months, analyst sentiment is consistently positive, with firms like BofA Securities and Wells Fargo maintaining Buy ratings. This support, anchored by a wide but high-potential revenue estimate range of $694.6M to $2.42B, suggests professional conviction in the long-term commercial opportunity for lorundrostat.
- Deeply Oversold Technical Position: Trading at $25.05, the stock sits near the lower end of its 52-week range ($12.59-$47.65), approximately 35% of the range's span, indicating it is deeply oversold. This technical setup, combined with a low beta of 0.482, suggests the potential for a significant rebound if positive clinical catalysts emerge, as the stock's movements are largely decoupled from broader market volatility.
- Improving Per-Share Burn Rate: While net losses persist, the net loss per share has improved sequentially from -$0.98 in Q4 2024 to -$0.40 in Q4 2025. This reduction in per-share burn rate, driven by share count increases from equity offerings, indicates the company is managing its capital efficiently to extend its operational runway.
Bearish
- Pre-Revenue with High, Persistent Cash Burn: The company has zero revenue and reported a net loss of $32.2M in Q4 2025, with a trailing-twelve-month free cash flow of -$142.4M. This significant and persistent cash burn necessitates frequent capital raises, which dilute existing shareholders, as evidenced by the increase in shares outstanding from 49.9M in Q4 2024 to 80.5M in Q4 2025.
- Extreme Valuation Uncertainty and Binary Risk: Valuation is entirely speculative, with no revenue to anchor traditional multiples. The wide dispersion in analyst revenue estimates (low: $694.6M, high: $2.42B) underscores the extreme binary risk; the stock's value hinges entirely on the success or failure of a single drug candidate, lorundrostat, making it highly vulnerable to clinical trial setbacks.
- Severe Price Downtrend and Weak Momentum: The stock is in a pronounced downtrend, down 34.94% over six months and 14.45% over the past month, severely underperforming the SPY. This persistent negative momentum, with the price recently testing lows near $23.28, reflects a lack of near-term catalysts and sustained selling pressure, signaling weak investor confidence.
- High Short Interest Indicating Skepticism: A short ratio of 8.25 indicates significant bearish sentiment and skepticism in the market regarding the company's near-term prospects. This high level of short interest can exacerbate downward price moves and create a headwind for any recovery, as short sellers may aggressively target the stock on any negative news.
MLYS Technical Analysis
The stock is in a pronounced downtrend from its 52-week highs, having declined 34.94% over the past six months and 5.79% over the last three months, significantly underperforming the broader market. Currently trading at $25.05, the price sits near the lower end of its 52-week range of $12.59 to $47.65, positioning it at approximately 35% of the range's span, which suggests the stock is deeply oversold and may represent a value opportunity, though it also indicates persistent negative momentum and a lack of near-term catalysts. Recent momentum remains weak, with the stock down 14.45% over the past month, a stark contrast to the SPY's 4.6% gain, highlighting severe relative weakness; this short-term decline accelerates the longer-term downtrend, signaling continued selling pressure and a lack of positive catalysts to arrest the slide. Key technical support is the 52-week low of $12.59, while resistance is the 52-week high of $47.65; a breakdown below the recent lows near $23.28 (from March 2026) would signal a potential test of the 52-week low, whereas a sustained move above the $30-$31 level is needed to suggest a reversal. The stock's beta of 0.482 indicates it is approximately 52% less volatile than the SPY, which is unusual for a biotech and suggests its price movements are driven more by idiosyncratic clinical and financing events than broad market swings.
Beta
0.56
0.56x market volatility
Max Drawdown
-51.7%
Largest decline past year
52-Week Range
$13-$48
Price range past year
Annual Return
+51.7%
Cumulative gain past year
| Period | MLYS Return | S&P 500 |
|---|---|---|
| 1m | -21.3% | -0.0% |
| 3m | -10.9% | +8.7% |
| 6m | -38.5% | +8.0% |
| 1y | +51.7% | +23.1% |
| ytd | -33.7% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MLYS Fundamental Analysis
As a pre-revenue clinical-stage biotech, Mineralys has no product sales, with revenue of $0 reported for the latest quarter (Q4 2025) and all prior periods, which is standard for its development phase. The company's financials are entirely defined by its R&D burn rate, with net losses of $32.2 million in Q4 2025, $36.9 million in Q3 2025, and $43.3 million in Q2 2025, showing some quarterly volatility but a consistent trend of significant operating losses as it advances lorundrostat through clinical trials. Gross and operating margins are not meaningful, given the lack of revenue, but the net loss per share has improved sequentially from -$0.98 in Q4 2024 to -$0.40 in Q4 2025, reflecting a reduction in the per-share burn rate due to share count increases from equity offerings. The balance sheet remains strong with a robust current ratio of 43.76 and zero debt, indicating ample liquidity; however, cash flow is deeply negative, with free cash flow of -$142.4 million (TTM) and operating cash flow of -$37.9 million in the latest quarter, necessitating periodic capital raises to fund operations, as evidenced by the $96.7 million in net cash from financing in Q4 2025 from common stock issuance.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-142431000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MLYS Overvalued?
Given the company has negative net income and negative EBITDA, the appropriate valuation metric is EV/Sales; however, with zero revenue, traditional sales-based multiples are not applicable, making the stock's valuation entirely a function of its cash-adjusted market cap relative to its clinical pipeline potential. The trailing Price-to-Book (P/B) ratio of 3.80 offers a limited lens, suggesting the market values the company's equity at a significant premium to its book value, primarily reflecting the value assigned to its intellectual property and cash reserves rather than tangible assets. In the absence of meaningful peer multiples due to the lack of revenue, valuation is driven by discounted cash flow models based on future sales projections for lorundrostat, with the wide dispersion in analyst revenue estimates for future years—ranging from $694.6 million to $2.42 billion—highlighting the extreme uncertainty and binary nature of the investment case.
PE
-15.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -23x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on the company's complete lack of revenue and substantial cash burn. With a TTM free cash flow of -$142.4 million and a quarterly operating cash burn averaging approximately -$38 million, the company is entirely dependent on external financing. This was demonstrated in Q4 2025 with a $96.7 million equity raise, which increased shares outstanding by over 60% year-over-year, leading to significant shareholder dilution. The risk is not insolvency—given the strong current ratio of 43.76 and zero debt—but rather continued dilution and the potential for financing to become more expensive or unavailable if clinical progress stalls.
Market & Competitive Risks are pronounced due to the stock's speculative valuation and competitive landscape. Trading at a P/B of 3.80, the market prices in significant future value for intellectual property, but this premium is vulnerable to compression if clinical timelines slip or competing therapies emerge. The stock's low beta of 0.482 indicates its fate is tied to idiosyncratic clinical events rather than the market, but this also means it lacks the buoyancy of a sector tailwind. The primary external threat is from established pharmaceutical companies and other biotechs developing next-generation hypertension and CKD treatments, which could diminish lorundrostat's commercial potential even if it gains approval.
Worst-Case Scenario involves a material clinical setback for lorundrostat, such as a failed pivotal trial or a significant safety issue identified by regulators. This would immediately invalidate the investment thesis, likely trigger analyst downgrades, and could lead to a financing crisis. In this adverse scenario, the stock would likely plummet towards its net cash value per share and test its 52-week low of $12.59. From the current price of $25.05, this represents a catastrophic downside of approximately -50%. A more realistic severe bear case, incorporating some residual option value, might see the stock fall to the $15-$18 range, still implying a loss of 28-40% from current levels.